Published January 31, 2023 | Version v1
Patent Open

Dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment

Contributors

Patent applicant:

Description

Provided herein are compositions and methods for detecting and/or targeting dysfunctional tumor antigen-specific CD8+ T cells in the tumor microenvironment for diagnostic, therapeutic and/or research applications. In particular, dysfunctional tumor antigen-specific CD8+ T cells are detected and/or targeted via their expression of cell surface receptors described herein, such as 4-1BB, LAG-3, or additional markers that correlate with 4-1BB and LAG-3 expression, such as markers differentially expressed on the surface of the T cells.

Files

US11566077.pdf

Files (5.1 MB)

Name Size Download all
md5:c67f0326d48de72fe1c6e7e1f31c5482
5.1 MB Preview Download

Additional details

Identifiers

Patent number
US 11566077 B2
Patent application number
US 201816476219 A
Other
oai:uchicago.tind.io:6690

Dates

Patent filed
2018-01-17

UChicago Information

Division(s)
Biological Sciences Division
Department(s)
Cancer Biology, Medicine